JP2020516594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516594A5 JP2020516594A5 JP2019554417A JP2019554417A JP2020516594A5 JP 2020516594 A5 JP2020516594 A5 JP 2020516594A5 JP 2019554417 A JP2019554417 A JP 2019554417A JP 2019554417 A JP2019554417 A JP 2019554417A JP 2020516594 A5 JP2020516594 A5 JP 2020516594A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- chain
- cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024024899A JP2024073459A (ja) | 2017-04-07 | 2024-02-21 | ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483298P | 2017-04-07 | 2017-04-07 | |
| US62/483,298 | 2017-04-07 | ||
| PCT/IB2018/000510 WO2018185564A2 (en) | 2017-04-07 | 2018-04-05 | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024024899A Division JP2024073459A (ja) | 2017-04-07 | 2024-02-21 | ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516594A JP2020516594A (ja) | 2020-06-11 |
| JP2020516594A5 true JP2020516594A5 (https=) | 2021-05-13 |
Family
ID=63713282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554417A Pending JP2020516594A (ja) | 2017-04-07 | 2018-04-05 | ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ |
| JP2024024899A Pending JP2024073459A (ja) | 2017-04-07 | 2024-02-21 | ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024024899A Pending JP2024073459A (ja) | 2017-04-07 | 2024-02-21 | ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200057048A1 (https=) |
| EP (1) | EP3607058A4 (https=) |
| JP (2) | JP2020516594A (https=) |
| KR (1) | KR20200004807A (https=) |
| CN (1) | CN110945120B (https=) |
| AU (1) | AU2018248961B2 (https=) |
| BR (1) | BR112019021022A2 (https=) |
| CO (1) | CO2019011018A2 (https=) |
| IL (1) | IL269846A (https=) |
| MX (1) | MX2019012058A (https=) |
| RU (1) | RU2019135533A (https=) |
| SG (1) | SG11201909290TA (https=) |
| WO (1) | WO2018185564A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| AU2014343379B2 (en) | 2013-11-04 | 2019-02-14 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
| EP3291832B1 (en) | 2015-05-06 | 2025-09-03 | UTI Limited Partnership | Nanoparticle compositions for sustained therapy |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| EP3833681A1 (en) * | 2018-08-06 | 2021-06-16 | Medigene Immunotherapies GmbH | Ha-1 specific t cell receptors and their use |
| GB201906127D0 (en) * | 2019-05-01 | 2019-06-12 | Immutep S A | Assays |
| JP7731805B2 (ja) * | 2019-05-23 | 2025-09-01 | ユーティアイ・リミテッド・パートナーシップ | 肝疾患の治療方法 |
| US20210222178A1 (en) * | 2020-01-11 | 2021-07-22 | Sivec Biotechnologies Llc | MICROBIAL SYSTEM FOR PRODUCTION AND DELIVERY OF EUKARYOTE-TRANSLATABLE mRNA TO EUKARYA |
| WO2021216787A1 (en) * | 2020-04-21 | 2021-10-28 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analysis of receptor interaction |
| AR122023A1 (es) * | 2020-05-06 | 2022-08-03 | Imcyse Sa | Péptidos y métodos para el tratamiento de esclerosis múltiple |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022056014A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| EP4405465A4 (en) * | 2021-09-21 | 2025-12-24 | Univ Monash | TREATMENT METHODS |
| CN113960003B (zh) * | 2021-10-20 | 2023-10-24 | 吉林大学 | 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器 |
| US11873507B2 (en) | 2021-11-29 | 2024-01-16 | Replicate Bioscience, Inc. | Compositions and methods for expression of IL-12 and IL-1RA |
| EP4249062A1 (en) * | 2022-03-24 | 2023-09-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
| CN115125205A (zh) * | 2022-06-14 | 2022-09-30 | 中国医学科学院生物医学工程研究所 | 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法 |
| WO2024248042A1 (ja) * | 2023-05-29 | 2024-12-05 | 国立大学法人 東京大学 | ＭｕＳＫを標的とする新規化合物及びその用途 |
| WO2025061917A1 (en) * | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US707993A (en) | 1901-05-16 | 1902-08-26 | Clinton J Warren | Machine for corking bottles. |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| CA2328108A1 (en) | 1998-05-07 | 1999-11-11 | The Regents Of The University Of California | Use of neglected target tissue antigens in modulation of immune responses |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| IL157335A0 (en) | 2001-03-13 | 2004-02-19 | Novartis Ag | Lentiviral packaging constructs |
| GB0417954D0 (en) * | 2004-08-12 | 2004-09-15 | Avidex Ltd | Cellulat TCR ligand assay method |
| CN101678090B (zh) | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
| EP2353004B1 (en) | 2008-11-12 | 2018-01-03 | Yeda Research and Development Co. Ltd. | Diagnosis of multiple sclerosis |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| KR20130124487A (ko) | 2010-09-29 | 2013-11-14 | 유티아이 리미티드 파트너쉽 | 생체적합성, 생흡수성 나노구를 사용하는 자가면역 질병의 치료방법 |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US8809057B2 (en) * | 2012-01-04 | 2014-08-19 | Raytheon Bbn Technologies Corp. | Methods of evaluating gene expression levels |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| JP6014440B2 (ja) | 2012-09-26 | 2016-10-25 | 日立オートモティブシステムズ株式会社 | 移動物体認識装置 |
| AU2014343379B2 (en) | 2013-11-04 | 2019-02-14 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
| ES2905615T3 (es) * | 2014-11-20 | 2022-04-11 | Promega Corp | Sistemas y métodos para evaluar moduladores de puntos de control inmunitario |
| EP3851450B1 (en) * | 2014-12-19 | 2024-11-27 | ETH Zürich | Chimeric antigen receptors and methods of use |
| EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| EP3291832B1 (en) * | 2015-05-06 | 2025-09-03 | UTI Limited Partnership | Nanoparticle compositions for sustained therapy |
| EA201792660A1 (ru) * | 2015-06-01 | 2018-05-31 | Медиджин Иммьюнотерапиз Гмбх | Библиотека т-клеточных рецепторов |
| CA2996887A1 (en) * | 2015-09-11 | 2017-03-16 | Agenus Inc. | Engineered host cells and methods of use thereof |
-
2018
- 2018-04-05 WO PCT/IB2018/000510 patent/WO2018185564A2/en not_active Ceased
- 2018-04-05 AU AU2018248961A patent/AU2018248961B2/en active Active
- 2018-04-05 BR BR112019021022A patent/BR112019021022A2/pt not_active Application Discontinuation
- 2018-04-05 US US16/603,180 patent/US20200057048A1/en not_active Abandoned
- 2018-04-05 SG SG11201909290T patent/SG11201909290TA/en unknown
- 2018-04-05 JP JP2019554417A patent/JP2020516594A/ja active Pending
- 2018-04-05 CN CN201880038292.4A patent/CN110945120B/zh active Active
- 2018-04-05 KR KR1020197032951A patent/KR20200004807A/ko not_active Withdrawn
- 2018-04-05 EP EP18781139.3A patent/EP3607058A4/en active Pending
- 2018-04-05 RU RU2019135533A patent/RU2019135533A/ru not_active Application Discontinuation
- 2018-04-05 MX MX2019012058A patent/MX2019012058A/es unknown
-
2019
- 2019-10-04 CO CONC2019/0011018A patent/CO2019011018A2/es unknown
- 2019-10-06 IL IL26984619A patent/IL269846A/en unknown
-
2023
- 2023-09-01 US US18/459,960 patent/US20240201171A1/en active Pending
-
2024
- 2024-02-21 JP JP2024024899A patent/JP2024073459A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516594A5 (https=) | ||
| CN110730821B (zh) | 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法 | |
| Park et al. | Mitochondrial DNA mutations in disease and aging | |
| JP7733865B2 (ja) | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 | |
| AU2017336100B2 (en) | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus | |
| ES2821655T5 (es) | Vectores de ADN no integrantes para la modificación genética de células | |
| RU2019135533A (ru) | Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах | |
| JP2018509151A5 (https=) | ||
| JP2017018125A5 (https=) | ||
| JP2017503485A (ja) | 遺伝子産物の発現、構造情報、及び誘導性モジュラーｃａｓ酵素を変更するためのｃｒｉｓｐｒ−ｃａｓ系並びに方法 | |
| US9127283B2 (en) | Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same | |
| US20230059921A1 (en) | Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents | |
| TWI900630B (zh) | 用於富集基因改造t細胞之方法 | |
| Anderson et al. | Regulation of the expression and activity of Unr in mammalian cells | |
| US12522818B2 (en) | Method for inducing deletion in genomic DNA | |
| Jumlongras et al. | An evolutionarily conserved enhancer regulates Bmp4 expression in developing incisor and limb bud | |
| Andersen et al. | Sperm 1: a POU-domain gene transiently expressed immediately before meiosis I in the male germ cell. | |
| CN104293815A (zh) | 一种纳米基因疫苗及其制备方法和应用 | |
| US8829177B2 (en) | Enhanced engineered native promoters and uses thereof | |
| Pouilhe et al. | Direct regulation of vHnf1 by retinoic acid signaling and MAF-related factors in the neural tube | |
| JP2009240233A5 (https=) | ||
| JP2013034401A (ja) | アストロサイトで遺伝子を発現させるためのベクター | |
| US20110173707A1 (en) | System for the Determination of Molecules Altering the Function of Interferon, Method Therefor and Compounds Altering Interferon Activity | |
| Whalen | Promoters, enhancers, and inducible elements for gene therapy | |
| US20240148792A1 (en) | Vector systems and methods of using same |